REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...
The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...
IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
